Header Logo

Connection

CHRISTIE BALLANTYNE to United States

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about United States.
CHRISTIE BALLANTYNE
Connection Strength
3.453
United States
  1. LDL cholesterol management simplified in adults-lower for longer is better: Guidance from the National Lipid Association. J Clin Lipidol. 2025 Sep-Oct; 19(5):1200-1207.
    View in: PubMed
    Score: 0.078
  2. Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system. J Clin Lipidol. 2025 May-Jun; 19(3):432-441.
    View in: PubMed
    Score: 0.077
  3. Recognition and management of persistent chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2025 Jul-Aug; 19(4):723-736.
    View in: PubMed
    Score: 0.077
  4. Lipoprotein(a) levels in a population with clinical atherosclerotic cardiovascular disease in the United States: A subanalysis from the Lp(a)HERITAGE study. J Clin Lipidol. 2025 Jan-Feb; 19(1):28-38.
    View in: PubMed
    Score: 0.075
  5. The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. Tex Heart Inst J. 2023 11 17; 50(6).
    View in: PubMed
    Score: 0.070
  6. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023 Mar-Apr; 17(2):208-218.
    View in: PubMed
    Score: 0.067
  7. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.060
  8. Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):114-121.
    View in: PubMed
    Score: 0.058
  9. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. J Am Heart Assoc. 2020 07 07; 9(13):e015405.
    View in: PubMed
    Score: 0.055
  10. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.052
  11. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
    View in: PubMed
    Score: 0.051
  12. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018 10; 16(10):1964-1972.
    View in: PubMed
    Score: 0.049
  13. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 10; 277:195-203.
    View in: PubMed
    Score: 0.048
  14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.048
  15. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis. 2018 01; 268:12-18.
    View in: PubMed
    Score: 0.046
  16. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017 07; 262:131-137.
    View in: PubMed
    Score: 0.045
  17. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.045
  18. 25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2016 11 07; 5(11).
    View in: PubMed
    Score: 0.043
  19. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol. 2016 May-Jun; 10(3):497-504.e4.
    View in: PubMed
    Score: 0.040
  20. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.039
  21. Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. Am J Cardiol. 2015 Aug 01; 116(3):481-4.
    View in: PubMed
    Score: 0.039
  22. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.036
  23. Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. Am J Cardiol. 2013 Nov 01; 112(9):1287-92.
    View in: PubMed
    Score: 0.034
  24. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.034
  25. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 Jul; 14(10):1409-16.
    View in: PubMed
    Score: 0.034
  26. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013 Apr; 44(4):961-7.
    View in: PubMed
    Score: 0.033
  27. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.031
  28. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
    View in: PubMed
    Score: 0.030
  29. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010 Apr 13; 55(15):1600-7.
    View in: PubMed
    Score: 0.027
  30. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.027
  31. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
    View in: PubMed
    Score: 0.025
  32. Prevalence of metabolic syndrome and associated risk factors in Asian Indians. J Immigr Minor Health. 2008 Aug; 10(4):313-23.
    View in: PubMed
    Score: 0.024
  33. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends? Crit Pathw Cardiol. 2007 Jun; 6(2):41-5.
    View in: PubMed
    Score: 0.022
  34. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007 Feb; 30(2):325-31.
    View in: PubMed
    Score: 0.022
  35. Linking Chronic Kidney Disease to Incident Heart Failure and Adverse Cardiac Remodeling Through the Plasma Proteome: The ARIC Study. JACC Heart Fail. 2025 Aug; 13(8):102512.
    View in: PubMed
    Score: 0.020
  36. Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project. J Am Heart Assoc. 2025 Jun 03; 14(11):e038608.
    View in: PubMed
    Score: 0.019
  37. Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults. J Thromb Haemost. 2025 Jul; 23(7):2235-2241.
    View in: PubMed
    Score: 0.019
  38. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
    View in: PubMed
    Score: 0.019
  39. Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
    View in: PubMed
    Score: 0.019
  40. Demographic and Clinical Risk Factors of Developing Clinically Recognized Varicose Veins in Older Adults. Am J Prev Med. 2025 Apr; 68(4):674-681.
    View in: PubMed
    Score: 0.019
  41. Association of left atrial function with frailty: The Atherosclerosis Risk in Communities (ARIC) study. J Am Geriatr Soc. 2024 Dec; 72(12):3810-3823.
    View in: PubMed
    Score: 0.019
  42. Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
    View in: PubMed
    Score: 0.019
  43. Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
    View in: PubMed
    Score: 0.019
  44. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004 Sep; 6(5):353-62.
    View in: PubMed
    Score: 0.019
  45. Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
    View in: PubMed
    Score: 0.018
  46. Anemia, Iron Deficiency, and Cause-Specific Mortality: The Atherosclerosis Risk in Communities Study. Gerontology. 2024; 70(10):1023-1032.
    View in: PubMed
    Score: 0.018
  47. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
    View in: PubMed
    Score: 0.018
  48. Associations of mid-to-late-life inflammation with late-life mobility and the influences of chronic comorbidities, race, and social determinants of health: The Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2024 Aug; 72(8):2434-2445.
    View in: PubMed
    Score: 0.018
  49. It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States. Glob Heart. 2024; 19(1):43.
    View in: PubMed
    Score: 0.018
  50. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
    View in: PubMed
    Score: 0.018
  51. Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 02 06; 83(5):562-573.
    View in: PubMed
    Score: 0.018
  52. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 01 02; 13(1):e032413.
    View in: PubMed
    Score: 0.018
  53. Trends in sleep apnea and heart failure related mortality in the United States from 1999 to 2019. Curr Probl Cardiol. 2024 Feb; 49(2):102342.
    View in: PubMed
    Score: 0.018
  54. County-Level Cardiologist Density and Mortality in the United States. J Am Heart Assoc. 2023 12 05; 12(23):e031686.
    View in: PubMed
    Score: 0.018
  55. Social Vulnerability and Cardiovascular-Related Mortality Among Older Adults in the United States. Am J Med. 2024 02; 137(2):122-127.e1.
    View in: PubMed
    Score: 0.017
  56. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
    View in: PubMed
    Score: 0.017
  57. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175.
    View in: PubMed
    Score: 0.017
  58. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
    View in: PubMed
    Score: 0.016
  59. Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 12 15; 161:42-50.
    View in: PubMed
    Score: 0.015
  60. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.015
  61. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.015
  62. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.015
  63. Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 09 07; 10(17):e020890.
    View in: PubMed
    Score: 0.015
  64. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
    View in: PubMed
    Score: 0.015
  65. Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
    View in: PubMed
    Score: 0.015
  66. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
    View in: PubMed
    Score: 0.015
  67. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.015
  68. The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8. J Am Coll Cardiol. 2021 06 15; 77(23):2939-2959.
    View in: PubMed
    Score: 0.015
  69. Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. J Am Assoc Nurse Pract. 2021 05 31; 33(11):967-974.
    View in: PubMed
    Score: 0.015
  70. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.014
  71. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.014
  72. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.014
  73. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021 04; 69(4):986-994.
    View in: PubMed
    Score: 0.014
  74. Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. Popul Health Manag. 2021 06; 24(3):414-415.
    View in: PubMed
    Score: 0.014
  75. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.014
  76. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.014
  77. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
    View in: PubMed
    Score: 0.014
  78. Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2020 09; 40(9):2322-2331.
    View in: PubMed
    Score: 0.014
  79. Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. Am J Med. 2020 11; 133(11):1293-1301.e1.
    View in: PubMed
    Score: 0.014
  80. Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. J Am Heart Assoc. 2020 05 18; 9(10):e014885.
    View in: PubMed
    Score: 0.014
  81. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med. 2000 May 08; 160(9):1361-9.
    View in: PubMed
    Score: 0.014
  82. Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
    View in: PubMed
    Score: 0.014
  83. Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2020 03 03; 9(5):e013560.
    View in: PubMed
    Score: 0.014
  84. The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk. Circulation. 2020 02 18; 141(7):592-599.
    View in: PubMed
    Score: 0.014
  85. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
    View in: PubMed
    Score: 0.013
  86. Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2019 12 31; 188(12):2146-2155.
    View in: PubMed
    Score: 0.013
  87. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.013
  88. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019 12 17; 140(25):2076-2088.
    View in: PubMed
    Score: 0.013
  89. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 02 04; 141(5):367-375.
    View in: PubMed
    Score: 0.013
  90. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.013
  91. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
    View in: PubMed
    Score: 0.013
  92. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.013
  93. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.013
  94. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.013
  95. Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. Am Heart J. 2019 10; 216:62-73.
    View in: PubMed
    Score: 0.013
  96. Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2019 09; 67(9):1795-1802.
    View in: PubMed
    Score: 0.013
  97. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019 09 01; 124(5):696-701.
    View in: PubMed
    Score: 0.013
  98. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.013
  99. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 07 15; 124(2):245-252.
    View in: PubMed
    Score: 0.013
  100. Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease. JACC Cardiovasc Imaging. 2019 07; 12(7 Pt 1):1292-1293.
    View in: PubMed
    Score: 0.013
  101. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.013
  102. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.012
  103. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.012
  104. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998 Nov 05; 82(9A):3Q-12Q.
    View in: PubMed
    Score: 0.012
  105. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thromb Haemost. 2018 Nov; 118(11):1940-1950.
    View in: PubMed
    Score: 0.012
  106. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
    View in: PubMed
    Score: 0.012
  107. Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Curr Atheroscler Rep. 2018 05 21; 20(7):35.
    View in: PubMed
    Score: 0.012
  108. Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults. J Am Heart Assoc. 2018 05 07; 7(10).
    View in: PubMed
    Score: 0.012
  109. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2018 07; 274:86-93.
    View in: PubMed
    Score: 0.012
  110. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.012
  111. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2018 03 01; 3(3):200-206.
    View in: PubMed
    Score: 0.012
  112. Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
    View in: PubMed
    Score: 0.012
  113. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.012
  114. Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. Am Heart J. 2018 03; 197:62-69.
    View in: PubMed
    Score: 0.012
  115. Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2018 01; 268:63-67.
    View in: PubMed
    Score: 0.012
  116. Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 02 15; 121(4):430-436.
    View in: PubMed
    Score: 0.012
  117. Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in Communities Study. Stroke. 2017 12; 48(12):3196-3202.
    View in: PubMed
    Score: 0.012
  118. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.011
  119. 2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
    View in: PubMed
    Score: 0.011
  120. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018 01; 93(1):252-259.
    View in: PubMed
    Score: 0.011
  121. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017 Oct; 192:19-25.
    View in: PubMed
    Score: 0.011
  122. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017 Sep; 36(9):2121-2128.
    View in: PubMed
    Score: 0.011
  123. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.011
  124. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.011
  125. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017 Mar 24; 6(4).
    View in: PubMed
    Score: 0.011
  126. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar; 40(3):138-148.
    View in: PubMed
    Score: 0.011
  127. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.011
  128. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.011
  129. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.011
  130. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
    View in: PubMed
    Score: 0.011
  131. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.011
  132. Obesity and Subtypes of Incident Cardiovascular Disease. J Am Heart Assoc. 2016 07 28; 5(8).
    View in: PubMed
    Score: 0.011
  133. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.010
  134. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
    View in: PubMed
    Score: 0.010
  135. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.010
  136. Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016 Jun; 49(9):657-662.
    View in: PubMed
    Score: 0.010
  137. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.010
  138. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.010
  139. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. 2015 Nov 24; 132(21):1979-89.
    View in: PubMed
    Score: 0.010
  140. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
    View in: PubMed
    Score: 0.010
  141. Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2015 Oct; 242(2):625-9.
    View in: PubMed
    Score: 0.010
  142. Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Nov; 170(5):961-7.
    View in: PubMed
    Score: 0.010
  143. Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015 Aug; 241(2):641-8.
    View in: PubMed
    Score: 0.010
  144. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85.
    View in: PubMed
    Score: 0.010
  145. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 2015 Jul; 61(7):938-47.
    View in: PubMed
    Score: 0.010
  146. The world and lipidology as it relates to cardiology. Cardiol Clin. 2015 May; 33(2):xiii-xiv.
    View in: PubMed
    Score: 0.010
  147. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015 Aug; 170(2):380-9.
    View in: PubMed
    Score: 0.010
  148. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
    View in: PubMed
    Score: 0.010
  149. N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens. 2015 Oct; 28(10):1262-6.
    View in: PubMed
    Score: 0.010
  150. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.010
  151. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord. 2015 Apr; 30(4):552-9.
    View in: PubMed
    Score: 0.009
  152. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.009
  153. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015 Apr; 62(4):841-7.
    View in: PubMed
    Score: 0.009
  154. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
    View in: PubMed
    Score: 0.009
  155. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.009
  156. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.009
  157. Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
    View in: PubMed
    Score: 0.009
  158. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.009
  159. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace. 2014 Oct; 16(10):1426-33.
    View in: PubMed
    Score: 0.009
  160. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014 Jul 15; 64(2):196-206.
    View in: PubMed
    Score: 0.009
  161. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014 Aug; 34(8):1770-7.
    View in: PubMed
    Score: 0.009
  162. Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. PLoS One. 2014; 9(3):e92469.
    View in: PubMed
    Score: 0.009
  163. Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
    View in: PubMed
    Score: 0.009
  164. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014 Apr; 35(15):960-8.
    View in: PubMed
    Score: 0.009
  165. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J. 2014 Mar; 167(3):342-349.e17.
    View in: PubMed
    Score: 0.009
  166. The editor's roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15; 112(8):1133-41.
    View in: PubMed
    Score: 0.009
  167. Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
    View in: PubMed
    Score: 0.009
  168. The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol. 2013 Aug 01; 178(3):401-9.
    View in: PubMed
    Score: 0.009
  169. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
    View in: PubMed
    Score: 0.008
  170. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.008
  171. The effect of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. Diabetes Res Clin Pract. 2012 Jul; 97(1):e6-8.
    View in: PubMed
    Score: 0.008
  172. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31; 59(5):484-9.
    View in: PubMed
    Score: 0.008
  173. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012 Jul; 27(7):2839-47.
    View in: PubMed
    Score: 0.008
  174. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
    View in: PubMed
    Score: 0.008
  175. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.007
  176. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24; 123(20):2292-333.
    View in: PubMed
    Score: 0.007
  177. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
    View in: PubMed
    Score: 0.007
  178. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. Int J Epidemiol. 2010 Dec; 39(6):1647-55.
    View in: PubMed
    Score: 0.007
  179. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetol. 2010 Dec; 47 Suppl 1:199-207.
    View in: PubMed
    Score: 0.007
  180. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009 May 05; 119(17):2408-16.
    View in: PubMed
    Score: 0.006
  181. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities study. Diabetes. 2009 Jan; 58(1):285-9.
    View in: PubMed
    Score: 0.006
  182. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
    View in: PubMed
    Score: 0.006
  183. APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum Mol Genet. 2008 Jul 01; 17(13):2039-46.
    View in: PubMed
    Score: 0.006
  184. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. 2008 May; 21(5):533-8.
    View in: PubMed
    Score: 0.006
  185. Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study. Ann Epidemiol. 2008 Feb; 18(2):101-7.
    View in: PubMed
    Score: 0.006
  186. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2007 May 01; 165(9):1047-54.
    View in: PubMed
    Score: 0.005
  187. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis. 2007 Oct; 194(2):e131-40.
    View in: PubMed
    Score: 0.005
  188. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006 Sep; 49(9):2086-96.
    View in: PubMed
    Score: 0.005
  189. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
    View in: PubMed
    Score: 0.005
  190. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2006 May; 186(1):74-9.
    View in: PubMed
    Score: 0.005
  191. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005 Aug; 28(8):2013-8.
    View in: PubMed
    Score: 0.005
  192. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004 Sep; 53(9):2473-8.
    View in: PubMed
    Score: 0.005
  193. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2004 Jan; 27(1):77-82.
    View in: PubMed
    Score: 0.004
  194. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003 Dec; 171(2):265-72.
    View in: PubMed
    Score: 0.004
  195. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003 Jul; 52(7):1799-805.
    View in: PubMed
    Score: 0.004
  196. Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2003 May; 26(5):1338-43.
    View in: PubMed
    Score: 0.004
  197. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar; 34(3):623-31.
    View in: PubMed
    Score: 0.004
  198. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.